OTC Markets OTCPK - Delayed Quote USD

MedMira Inc. (MMIRF)

0.0207

0.0000

(0.00%)

At close: April 15 at 4:00:00 PM EDT

MedMira Second Quarter 2025 Earnings: CA$0.002 loss per share (vs CA$0.001 loss in 2Q 2024)

MedMira ( CVE:MIR ) Second Quarter 2025 Results Key Financial Results Net loss: CA$1.20m (loss widened by 103% from 2Q...

Simply Wall St. 9 days ago

MMIRF
0.00%
MedMira Reports Second Quarter Results FY2025

HALIFAX, NS / ACCESS Newswire / April 1, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2025. Corporate update In Q2 FY2025, MedMira has received the Health Canada approval of its ...

ACCESS Newswire 14 days ago

MMIRF
0.00%
MedMira Announces Partnership with MediGroup Physician Services in the United States

HALIFAX, NS / ACCESS Newswire / February 27, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today its partnership with MediGroup, a leader in the US health care industry since 1999. This new partnership allows the Company to promote and sell its ...

ACCESS Newswire last month

MMIRF
0.00%
MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada

HALIFAX, NS / ACCESS Newswire / February 25, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today its exclusive distribution agreement with Trimedic Inc. for the Canadian market. This partnership allows MedMira to expedite its growth in the Canadian ...

ACCESS Newswire last month

MMIRF
0.00%
MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications

MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clinical trials for new label claim applications of its recently Health Canada approved Multiplo® TP/HIV ...

ACCESS Newswire 2 months ago

MMIRF
0.00%
MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use

MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test (Reveal® HIV test) for Point-of-Care (POC) use. The Reveal® HIV rapid test has achieved a sensitivity ...

ACCESS Newswire 2 months ago

MMIRF
0.00%
MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test

HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trials for its Multiplo® Complete Syphilis (TP/nTP) ...

ACCESS Newswire 3 months ago

MMIRF
0.00%
MedMira Reports First Quarter Results FY2025

HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2024. Corporate update During Q1 FY2025, MedMira has been continuing its regulatory work and ...

ACCESS Newswire 3 months ago

MMIRF
0.00%
Health Canada approves MedMira’s rapid test for HIV and syphilis

The test enables healthcare professionals to identify HIV-1/2 and syphilis antibodies from a single finger prick sample.

Medical Device Network 3 months ago

MMIRF
0.00%
TSX Venture Exchange Stock Maintenance Bulletins

TSX VENTURE COMPANIES

CNW Group 3 months ago

CBUTF

WWTIF

MMIRF
0.00%
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV

HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Rapid TP/HIV Test (Multiplo® TP/HIV) to be rolled ...

ACCESS Newswire 3 months ago

MMIRF
0.00%
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results

HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. Corporate Update In December 2023, the Company received the 510(k) (FDA) approval ...

ACCESS Newswire 4 months ago

MMIRF
0.00%
MedMira Announces the appointment of Vice President of Commercial Operations

MedMira Inc. continues its North-American expansion plan HALIFAX, NS / ACCESSWIRE / October 3, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) today announced the appointment of Nicole Crenshaw as Vice President of Commercial Operations, effective ...

ACCESS Newswire 6 months ago

MMIRF
0.00%
Clinical Trials to get Underway with Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada

HALIFAX, NS / ACCESSWIRE / August 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces it will conduct full clinical trials for its unique Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP) with the goal of getting it licensed ...

ACCESS Newswire 7 months ago

MMIRF
0.00%
MedMira Reports Third Quarter Results FY2024

HALIFAX, NS / ACCESSWIRE / July 2, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2024. Corporate update In Q3 FY2024, MedMira focused on the launch of MedMira's latest US FDA approved ...

ACCESS Newswire 9 months ago

MMIRF
0.00%
MedMira Announces the Hire of Vice President of Business Development

HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of Vice President of Business Development. Ms. Bell ...

ACCESS Newswire 11 months ago

MMIRF
0.00%

Performance Overview

Return	MMIRF	S&P/TSX Composite index (^GSPTSE)
YTD	+58.02%	-2.24%
1-Year	-65.50%	+10.71%
3-Year	-76.53%	+10.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MedMira Inc. (MMIRF)

MedMira Second Quarter 2025 Earnings: CA$0.002 loss per share (vs CA$0.001 loss in 2Q 2024)

MedMira Reports Second Quarter Results FY2025

MedMira Announces Partnership with MediGroup Physician Services in the United States

MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada

MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications

MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use

MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test

MedMira Reports First Quarter Results FY2025

Health Canada approves MedMira’s rapid test for HIV and syphilis

TSX Venture Exchange Stock Maintenance Bulletins

MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV

MedMira Reports FY2024 Fourth Quarter and Year End Financial Results

MedMira Announces the appointment of Vice President of Commercial Operations

Clinical Trials to get Underway with Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada

MedMira Reports Third Quarter Results FY2024

MedMira Announces the Hire of Vice President of Business Development

Performance Overview